Kisilea (Icatibant)

Icatibant is a selective antagonist of the bradykinin B2 receptor. By blocking this receptor, it prevents bradykinin‑mediated vasodilation and increased vascular permeability, which are responsible for the swelling seen in HAE attacks.

The prescribed dose of Kisilea is determined by the treating physician based on the patient’s clinical condition. The medication is supplied as a 30 mg/1 mL injectable solution for subcutaneous administration.

Safety data for Kisilea in pregnancy and lactation are limited. It should only be used if the potential benefit outweighs the potential risk to the fetus or infant, and the decision should be made by a qualified healthcare professional.

To order Kisilea, submit an enquiry on the product page at gnhindia.com specifying the required quantity. GNH India supplies hospitals, pharmacies and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details (including cold‑chain where required) and import documentation.

Kisilea (icatibant) is a bradykinin B2 receptor antagonist, whereas other HAE therapies such as C1‑inhibitor concentrates replace the deficient protein. Kisilea offers a subcutaneous route and rapid onset, making it convenient for self‑administration during attacks.

Kisilea should be stored at 2‑8 °C in a refrigerator. Keep the product in its original packaging, protect it from light, and do not freeze or shake the vial before use.

Kisilea is administered as a subcutaneous injection. The 30 mg/1 mL solution is injected into the subcutaneous tissue, typically in the abdomen or thigh, by a healthcare professional or trained patient following the prescriber’s instructions.

Serious risks include hypersensitivity reactions such as anaphylaxis, severe hypotension, and rare cases of angioedema unrelated to HAE. Patients should be monitored for any signs of severe allergic response after injection.

Kisilea should not be used by individuals with known hypersensitivity to icatibant or any of its excipients. Caution is also advised for patients with severe renal impairment, uncontrolled hypertension, or those receiving ACE inhibitors or ARBs without medical supervision.